BioSig up on start of mid-stage study of merimipodib in COVID-19

BioSig Technologies (BSGM +7.8%) subsidiary ViralClear Pharmaceuticals announces the start of enrollment in a Phase 2 clinical trial evaluating antiviral merimipodib, combined with Gilead Sciences’ (GILD +2.3%) remdesivir, in adult COVID-19 patients compared to remdesivir + placebo.

The primary endpoints are safety and the number of subjects not hospitalized or if hospitalized, free of respiratory failure, through day 28.

https://seekingalpha.com/news/3590719-biosig-up-8-on-start-of-mid-stage-study-of-merimipodib-in-covidminus-19